Newsletter

June 2021 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: June Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 23% Other stats: Number of signals over $10/share 4 Number […]

0Comments

May 2021 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: May Scorecard Number of Signals 6 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 10% Other stats: Number of signals over $10/share 2 Number […]

0Comments

April 2021 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: April Scorecard Number of Signals 10 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 5 Number […]

0Comments

March 2021 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: March Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 4% Other stats: Number of signals over $10/share 9 Number […]

0Comments

February 2021 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: February Scorecard Number of Signals 7 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 6 Number […]

0Comments

KemPharm gets FDA Approval for AZSTARYS™ to Treat ADHD

On March 2, KemPharm, Inc. (KMPH) announced that the FDA approved its New Drug Application (NDA) for the drug AZSTARYS™ (formerly referred to as KP415). The drug is a once-daily treatment for patients six-years-old and above who have attention deficit hyperactivity disorder (ADHD). AZSTARYS™ should be available as early as the second half of 2021 […]

0Comments

January 2021 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 6 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 14% Other stats: Number of signals over $10/share 5 Number […]

0Comments

Sorrento Therapeutics Reports Promising Phase 1b Results of COVI-MSC in COVID ICU Patients

On January 26, Sorrento Therapeutics, Inc.  (SRNE) announced preliminary results from a Phase 1b study of COVID-MSC for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). COVI-MSC is an infusion treatment of human allogeneic adipose-derived mesenchymal stem cells. The three patients in the study experienced no infusion-related adverse effects and […]

0Comments

December 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 96% Avg Increase – Next open to 5-day Peak 12% Other stats: Number of signals over $10/share 16 Number […]

0Comments

Curis Updates Phase 1 Clinical Trial Results for Non-Hodgkin’s Lymphoma Treatment

On December 8, Curis, Inc. (CRIS) presented updated data on its Phase 1 clinical trial of CA-4948, an IRAK4 kinase inhibitor to treat patients with relapsed or refractory (R/R) non-Hodgkin’s lymphoma (NHL). The treatments was well tolerated by patients, and 6 out of 7 experienced anti-cancer activity marked by a decrease in tumor burden. As […]

0Comments

Latest of Knowledge Center

Latest of Newsletters